IPP Bureau
EU approves Evusheld to prevent Covid-19
By IPP Bureau - March 28, 2022
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
EU and European Disability Forum laud efforts of Sightsavers in India
By IPP Bureau - March 28, 2022
This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities
Free guide to Colorectal Cancer Screening now available in Hindi
By IPP Bureau - March 28, 2022
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
Vela Diagnostics launches NGS-based pan-cancer panels
By IPP Bureau - March 28, 2022
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Live Pharma Coalition organised its first-ever pharma conclave in Mumbai
By IPP Bureau - March 28, 2022
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Philips expands network of clinical partners for early diagnosis and treatment of lung cancer
By IPP Bureau - March 28, 2022
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Tata Capital Healthcare Fund II raises Rs 955 crore
By IPP Bureau - March 28, 2022
The fund will take equity positions in India-focused healthcare and life sciences-related companies
NTT DATA launches hackathon for AI innovations in healthcare
By IPP Bureau - March 28, 2022
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
New spesolimab data show promising results in patients with generalised pustular psoriasis flares
By IPP Bureau - March 28, 2022
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Aurobindo enters domestic formulations space with the acquisition of Veritaz for Rs 171 Cr
By IPP Bureau - March 28, 2022
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
ILC Dover launches liquid single-use bioprocessing bags for biotherapeutics market
By IPP Bureau - March 28, 2022
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis
By IPP Bureau - March 27, 2022
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Aster DM Healthcare signs MoU with Tamil Nadu govt to invest Rs. 500 crore
By IPP Bureau - March 27, 2022
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
NMPA approves Hansizhuang, its first monoclonal antibody
By IPP Bureau - March 27, 2022
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
ScienceMedia and Apex Mobile Clinical Research sign partnership for clinical trial training
By IPP Bureau - March 27, 2022
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
